|
APRIL 17 |
|
6:00 pm - 6:15 |
Welcome Notes |
Ratan Bhat and Bengt Winblad,
CONFERENCE CHAIRS |
|
6:15-7:15 |
Keynote Lecture |
Peter St. George Hyslop |
|
7:30 |
Welcome Reception |
|
APRIL 18 |
|
|
Session I |
Frank LaFerla, CHAIR |
Modulators of AD Neuropathology |
|
8:00-8:25am |
|
Malcolm Leissring |
ß-amyloid Degradation: The
Inside Story |
|
8:25-8:50 |
|
William Van Nostrand |
Cerebral Microvascular Amyloid:
Neuroinflammation and Cognitive
Deficits |
|
8:50-9:15 |
|
Frank LaFerla |
Factors Modulating the
Pathological and Cognitive
Phenotype in Alzheimer's Mice |
|
|
Session II |
Ratan Bhat, CHAIR |
Disease Modification Strategies
for Alzheimer's disease |
|
9:15-9:40 |
|
Ratan Bhat |
GSK3 Inhibitors for Alzheimer's
Disease |
|
9:40-10:05 |
|
Susanne Fabre |
Translational Biomarkers for
Disease Modification in
Alzheimer's Disease |
|
10:05-10:20 |
Break |
|
10:20-10:45 |
|
Sharon Schaham |
TBA |
|
10:45-11:10 |
|
Grant Krafft |
Stable Trimeric A-Beta Peptides:
Potential Vaccine Immunogens to
Prevent ADDL-Triggered Memory
Deficits |
|
|
Session III |
Eric Karran, CHAIR |
Gamma-secretase: Functionality
and Pharmacology |
|
11:10-11:35 |
|
Alexandra Tolia |
γ-Secretase: Past, Present,
Future |
|
11:35am-12:00pm |
|
Mark Shearman |
Exploiting the Varied
Pharmacology of the γ-Secretase
Complex |
|
12:00:12:25 |
|
Eric Karran |
LY450139: Testing the Amyloid
Cascade Hypothesis in Man |
|
12:25pm-2:00 |
Lunch |
|
|
Session IV |
Bengt Winblad, CHAIR |
Genetics and Treatment
Strategies for Alzheimer's
Disease |
|
2:00-2:25 |
|
Caroline Graff |
Clinical Genetics in Alzheimer's
Disease |
|
2:25-2:50 |
|
Khalid Iqbal |
Biomarkers in CSF |
|
2:50-3:15 |
|
Pradeep Banerjee |
Memantine Lowers Brain Beta-Amyloid
Levels and Improves Cognitive
Performance in Models of
Alzheimer’s Disease |
|
3:15-3:40 |
|
Bengt Winblad |
Treatment Strategies in Severe
Alzheimer's Disease |
|
9:00 pm |
Networking Reception |
|
APRIL 19 |
|
|
Session V |
Richard Cowburn, CHAIR |
Imaging and Modulation of
Neuropatholgies |
|
8:30-8:55 am |
|
Angel Cedazo-Minguez |
Mechanisms of ApoE Contribution
to Alzheimer's Disease |
|
8:55-9:20 |
|
Brian Backskai |
A View into the Alzheimer's
Brain with Optical Imaging |
|
9:20-9:45 |
|
Samuel Svensson |
AZAD a High Resolution PET
Tracer for Imaging of Abeta
Amyloid Plaques |
|
9:45-10:10 |
|
Richard Cowburn |
Cholesterol Modifying Strategies
for Alzheimer's Disease |
|
10:10-10:25 |
Break |
|
|
Session VI |
Dave Morgan, CHAIR |
Immunotherapy for Alzheimer's
Disease |
|
10:25-10:50 |
|
Cindy Lemere |
Complement C3 Deficiency Leads
to Increased Plaque Burden and
Neuronal Loss in APP Tg Mice but
Does not Inlfuence A-beta
Clearance by Immunotherapy |
|
10:50-11:15 |
|
David Cribbs |
DNA Vaccines for Alzheimer’s
Disease which Combine Non-Self
T-Cell Epitopes with Molecular
Adjuvants that Utilize the
Innate Immune System to Drive a
Th2-Mediated Antibody Response |
|
11:15-11:40 |
|
Dave Morgan |
Clearance of Amyloid by Active
Immunotherapy Has Different
Consequences than Clearance by
An NSAID |
|
11:40am-1:15pm |
Lunch |
|
|
Session VII |
Christian Haass, CHAIR |
Aß-Peptide: Generation,
Neurotoxicity & Treatment
Strategies |
|
1:15-1:40 |
|
Ottavio Arancio |
Alzheimer's Disease: Defeating
it at the Synapse |
|
1:40-2:05 |
|
Roger Nitsch |
Immunotherapy of Alzheimer's
Disease |
|
2:05-2:30 |
|
Lars Tjernberg |
Screen for Polymerization
Inhibitors |
|
2:30-2:50 |
|
Christian Haas |
Regulated Intramembrane
Proteolysis in Alzheimer's
Disease |
|
2:50-3:05 |
Break |
|
|
Session VIII |
Stefan Berg, CHAIR |
The Role of BACE Inhibition in
Alzheimer's Disease |
|
3:05-3:30 |
|
Robert Vassar |
The Beta-Secretase, BACE1: A
Potential Therapeutic Target for
Alzheimer's Disease |
|
3:30-3:55 |
|
Hemaka A. Rajapakse |
The Discovery of Non
Transition-State Isostere BACE
Inhibitors |
|
3:55-4:20 |
|
Stefan Berg |
Novel GSK3 Inhibitors for the
Treatment of Neurodegenerative
Diseases |
|
APRIL 20 |
|
|
Session IX |
John Hardy, CHAIR |
Genetic Implication of Tau in
Alzheimer's Pathogenesis |
|
8:00-8:25 am |
|
Rosa Rademakers |
The Role of Progranulin in
Dementia |
|
8:25-8:50 |
|
Mike Vitek |
Nos2 Deletion Results in Amyloid
Redistribution and Neurovascular
Changes in Two Different Mouse
Models of Amyloid Deposition |
|
8:50-9:15 |
|
John Hardy |
Genetic Dissection of the
Etiologies and Pathogeneses of
Alzheimer’s and Parkinson’s
Diseases and Related Disorders |
|
9:15-9:30 |
Break |
|
|
Session X |
Karen Duff, CHAIR |
Degradation, Aggregation and
Phosphorylation: Pathogenic
Potential and Therapeutic
Opportunities in Alzheimer's
Disease |
|
9:30-9:55 |
|
Gabriela Chiosis |
Roles of Heat Shock Protein 90
in Maintaining and Facilitating
the Degenerative Phenotype in
Tauopathy |
|
9:55-10:20 |
|
Jeffrey Kuret |
Mechanisms of Tau Aggregation:
How Do Post-Translational
Modifications and Tau Splicing
Mutations Promote
Neurofibrillary Lesion
Formation? |
|
10:20-10:45 |
|
Karen Duff |
Aberrant Phosphorylation as a
Pathogenic Mechanism in
Alzheimer's Disease |
|
10:45-11:00 |
Ending Notes |
Ratan Bhat and Bengt Winblad |
